Capricor Therapeutics, Inc. They specialize in the development of biologics, particularly cell and exosome-based technologies, to treat a wide range of diseases. Their leading product is CAP-1002, a cell therapy designed to treat Duchenne muscular dystrophy (DMD), a severe form of muscular dystrophy that leads to muscle degeneration and premature death.

CAP-1002 consists of allogeneic cardiosphere-derived cells (CDCs) that have immunomodulatory, anti-inflammatory, and anti-fibrotic effects. These effects are mediated by secreted exosomes containing microRNAs, which can alter gene expression and promote tissue regeneration. Additionally, Capricor is at the forefront of advancing exosome-based technology, leveraging nanosized particles with biologically active contents to direct or re-direct cellular activities.

With their focus on precision-engineered exosome platform technology, Capricor seeks to deliver targeted sets of effector molecules, potentially establishing a robust pipeline of innovative therapeutic candidates